Apogee Therapeutics Inc

Apogee Therapeutics reports FY‑2025 losses but pushes the pipeline forward with Zumilokibart, a promising candidate for atopic dermatitis and COPD. Read the latest financial overview and prospects for the biotech company.

Apogee Therapeutics Inc. experienced a significant week, marked by unusual options trading, insider activity, and positive clinical trial results for its anti-IL-13 antibody APG777.

Apogee Therapeutics, Inc. is a biotech company making waves with its innovative approach to developing antibody therapeutics for unmet medical needs, particularly in inflammatory and immune diseases.

Apogee Therapeutics, Inc. is a pioneering biotech company developing innovative antibody therapeutics to address unmet medical needs in conditions such as atopic dermatitis and COPD.

Apogee Therapeutics, a biotech company, is focused on developing innovative antibody therapeutics for inflammatory and immune diseases, positioning itself as a key player in the industry.